Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Research Report 2026(Status and Outlook)
Antibody-drug conjugates (ADCs) are a type of targeted biologics that connect cytotoxic drugs to monoclonal antibodies through linkers, which can be efficiently transported to target tumor cells to exert anti-tumor effects. CMO and CDMO companies specialize in drug production services, with a main focus on customized production during drug research and development and commercial production after market launch.
The global Antibody-drug Conjugates (ADCs) CMO and CDMO market size was estimated at USD 3863.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 19.00% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Antibody-drug Conjugates (ADCs) CMO and CDMO market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Antibody-drug Conjugates (ADCs) CMO and CDMO market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Antibody-drug Conjugates (ADCs) CMO and CDMO market.
Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Lonza Group
Merck KGaA
WuXi XDC
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Axplora
Aji Bio-Pharma
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
TOT Biopharm
Huadong Medicine
Innovent Biologics
Shanghai Henlius Biotech
Market Segmentation (by Type)
Cleavable linkers
Non-cleavable linkers
Market Segmentation (by Application)
Solid Tumors
Hematological Malignanciesncies
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Antibody-drug Conjugates (ADCs) CMO and CDMO Market
Overview of the regional outlook of the Antibody-drug Conjugates (ADCs) CMO and CDMO Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antibody-drug Conjugates (ADCs) CMO and CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Antibody-drug Conjugates (ADCs) CMO and CDMO, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Antibody-drug Conjugates (ADCs) CMO and CDMO market size was estimated at USD 3863.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 19.00% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Antibody-drug Conjugates (ADCs) CMO and CDMO market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Antibody-drug Conjugates (ADCs) CMO and CDMO market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Antibody-drug Conjugates (ADCs) CMO and CDMO market.
Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Lonza Group
Merck KGaA
WuXi XDC
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Axplora
Aji Bio-Pharma
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
TOT Biopharm
Huadong Medicine
Innovent Biologics
Shanghai Henlius Biotech
Market Segmentation (by Type)
Cleavable linkers
Non-cleavable linkers
Market Segmentation (by Application)
Solid Tumors
Hematological Malignanciesncies
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Antibody-drug Conjugates (ADCs) CMO and CDMO Market
Overview of the regional outlook of the Antibody-drug Conjugates (ADCs) CMO and CDMO Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antibody-drug Conjugates (ADCs) CMO and CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Antibody-drug Conjugates (ADCs) CMO and CDMO, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Antibody-drug Conjugates (ADCs) CMO and CDMO
1.2 Key Market Segments
1.2.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Segment by Type
1.2.2 Antibody-drug Conjugates (ADCs) CMO and CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Product Life Cycle
3.3 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Manufacturers (2020-2025)
3.4 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Manufacturers (2020-2025)
3.5 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Competitive Situation and Trends
3.8.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Concentration Rate
3.8.2 Global 5 and 10 Largest Antibody-drug Conjugates (ADCs) CMO and CDMO Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO INDUSTRY CHAIN ANALYSIS
4.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Antibody-drug Conjugates (ADCs) CMO and CDMO Market
5.7 ESG Ratings of Leading Companies
6 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Type (2020-2025)
6.3 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025)
6.4 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Price by Type (2020-2025)
7 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Sales by Application (2020-2025)
7.3 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) by Application (2020-2025)
7.4 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Growth Rate by Application (2020-2025)
8 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET SALES BY REGION
8.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region
8.1.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region
8.1.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Region
8.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region
8.2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region
8.2.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region
8.3 North America
8.3.1 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country
8.3.2 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country
8.4.2 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region
8.5.2 Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country
8.6.2 South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region
8.7.2 Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET PRODUCTION BY REGION
9.1 Global Production of Antibody-drug Conjugates (ADCs) CMO and CDMO by Region(2020-2025)
9.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Region (2020-2025)
9.3 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Production
9.4.1 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Production Growth Rate (2020-2025)
9.4.2 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Production
9.5.1 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Production Growth Rate (2020-2025)
9.5.2 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Production (2020-2025)
9.6.1 Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Production Growth Rate (2020-2025)
9.6.2 Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Antibody-drug Conjugates (ADCs) CMO and CDMO Production (2020-2025)
9.7.1 China Antibody-drug Conjugates (ADCs) CMO and CDMO Production Growth Rate (2020-2025)
9.7.2 China Antibody-drug Conjugates (ADCs) CMO and CDMO Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Lonza Group
10.1.1 Lonza Group Basic Information
10.1.2 Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.1.3 Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.1.4 Lonza Group Business Overview
10.1.5 Lonza Group SWOT Analysis
10.1.6 Lonza Group Recent Developments
10.2 Merck KGaA
10.2.1 Merck KGaA Basic Information
10.2.2 Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.2.3 Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.2.4 Merck KGaA Business Overview
10.2.5 Merck KGaA SWOT Analysis
10.2.6 Merck KGaA Recent Developments
10.3 WuXi XDC
10.3.1 WuXi XDC Basic Information
10.3.2 WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.3.3 WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.3.4 WuXi XDC Business Overview
10.3.5 WuXi XDC SWOT Analysis
10.3.6 WuXi XDC Recent Developments
10.4 Abbvie
10.4.1 Abbvie Basic Information
10.4.2 Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.4.3 Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.4.4 Abbvie Business Overview
10.4.5 Abbvie Recent Developments
10.5 Piramal Pharma Solutions
10.5.1 Piramal Pharma Solutions Basic Information
10.5.2 Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.5.3 Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.5.4 Piramal Pharma Solutions Business Overview
10.5.5 Piramal Pharma Solutions Recent Developments
10.6 Catalent
10.6.1 Catalent Basic Information
10.6.2 Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.6.3 Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.6.4 Catalent Business Overview
10.6.5 Catalent Recent Developments
10.7 Sterling Pharma Solutions
10.7.1 Sterling Pharma Solutions Basic Information
10.7.2 Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.7.3 Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.7.4 Sterling Pharma Solutions Business Overview
10.7.5 Sterling Pharma Solutions Recent Developments
10.8 Axplora
10.8.1 Axplora Basic Information
10.8.2 Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.8.3 Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.8.4 Axplora Business Overview
10.8.5 Axplora Recent Developments
10.9 Aji Bio-Pharma
10.9.1 Aji Bio-Pharma Basic Information
10.9.2 Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.9.3 Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.9.4 Aji Bio-Pharma Business Overview
10.9.5 Aji Bio-Pharma Recent Developments
10.10 BSP Pharmaceuticals
10.10.1 BSP Pharmaceuticals Basic Information
10.10.2 BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.10.3 BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.10.4 BSP Pharmaceuticals Business Overview
10.10.5 BSP Pharmaceuticals Recent Developments
10.11 Cerbios-Pharma
10.11.1 Cerbios-Pharma Basic Information
10.11.2 Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.11.3 Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.11.4 Cerbios-Pharma Business Overview
10.11.5 Cerbios-Pharma Recent Developments
10.12 Goodwin Biotechnology
10.12.1 Goodwin Biotechnology Basic Information
10.12.2 Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.12.3 Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.12.4 Goodwin Biotechnology Business Overview
10.12.5 Goodwin Biotechnology Recent Developments
10.13 TOT Biopharm
10.13.1 TOT Biopharm Basic Information
10.13.2 TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.13.3 TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.13.4 TOT Biopharm Business Overview
10.13.5 TOT Biopharm Recent Developments
10.14 Huadong Medicine
10.14.1 Huadong Medicine Basic Information
10.14.2 Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.14.3 Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.14.4 Huadong Medicine Business Overview
10.14.5 Huadong Medicine Recent Developments
10.15 Innovent Biologics
10.15.1 Innovent Biologics Basic Information
10.15.2 Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.15.3 Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.15.4 Innovent Biologics Business Overview
10.15.5 Innovent Biologics Recent Developments
10.16 Shanghai Henlius Biotech
10.16.1 Shanghai Henlius Biotech Basic Information
10.16.2 Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.16.3 Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.16.4 Shanghai Henlius Biotech Business Overview
10.16.5 Shanghai Henlius Biotech Recent Developments
11 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET FORECAST BY REGION
11.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast
11.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country
11.2.3 Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Region
11.2.4 South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Antibody-drug Conjugates (ADCs) CMO and CDMO by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type (2026-2035)
12.1.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type (2026-2035)
12.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Forecast by Application (2026-2035)
12.2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) Forecast by Application
12.2.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Antibody-drug Conjugates (ADCs) CMO and CDMO
1.2 Key Market Segments
1.2.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Segment by Type
1.2.2 Antibody-drug Conjugates (ADCs) CMO and CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Product Life Cycle
3.3 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Manufacturers (2020-2025)
3.4 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Manufacturers (2020-2025)
3.5 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Competitive Situation and Trends
3.8.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Concentration Rate
3.8.2 Global 5 and 10 Largest Antibody-drug Conjugates (ADCs) CMO and CDMO Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO INDUSTRY CHAIN ANALYSIS
4.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Antibody-drug Conjugates (ADCs) CMO and CDMO Market
5.7 ESG Ratings of Leading Companies
6 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Type (2020-2025)
6.3 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025)
6.4 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Price by Type (2020-2025)
7 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Sales by Application (2020-2025)
7.3 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) by Application (2020-2025)
7.4 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Growth Rate by Application (2020-2025)
8 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET SALES BY REGION
8.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region
8.1.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region
8.1.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Region
8.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region
8.2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region
8.2.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region
8.3 North America
8.3.1 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country
8.3.2 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country
8.4.2 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region
8.5.2 Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country
8.6.2 South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region
8.7.2 Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET PRODUCTION BY REGION
9.1 Global Production of Antibody-drug Conjugates (ADCs) CMO and CDMO by Region(2020-2025)
9.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Region (2020-2025)
9.3 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Production
9.4.1 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Production Growth Rate (2020-2025)
9.4.2 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Production
9.5.1 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Production Growth Rate (2020-2025)
9.5.2 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Production (2020-2025)
9.6.1 Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Production Growth Rate (2020-2025)
9.6.2 Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Antibody-drug Conjugates (ADCs) CMO and CDMO Production (2020-2025)
9.7.1 China Antibody-drug Conjugates (ADCs) CMO and CDMO Production Growth Rate (2020-2025)
9.7.2 China Antibody-drug Conjugates (ADCs) CMO and CDMO Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Lonza Group
10.1.1 Lonza Group Basic Information
10.1.2 Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.1.3 Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.1.4 Lonza Group Business Overview
10.1.5 Lonza Group SWOT Analysis
10.1.6 Lonza Group Recent Developments
10.2 Merck KGaA
10.2.1 Merck KGaA Basic Information
10.2.2 Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.2.3 Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.2.4 Merck KGaA Business Overview
10.2.5 Merck KGaA SWOT Analysis
10.2.6 Merck KGaA Recent Developments
10.3 WuXi XDC
10.3.1 WuXi XDC Basic Information
10.3.2 WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.3.3 WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.3.4 WuXi XDC Business Overview
10.3.5 WuXi XDC SWOT Analysis
10.3.6 WuXi XDC Recent Developments
10.4 Abbvie
10.4.1 Abbvie Basic Information
10.4.2 Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.4.3 Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.4.4 Abbvie Business Overview
10.4.5 Abbvie Recent Developments
10.5 Piramal Pharma Solutions
10.5.1 Piramal Pharma Solutions Basic Information
10.5.2 Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.5.3 Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.5.4 Piramal Pharma Solutions Business Overview
10.5.5 Piramal Pharma Solutions Recent Developments
10.6 Catalent
10.6.1 Catalent Basic Information
10.6.2 Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.6.3 Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.6.4 Catalent Business Overview
10.6.5 Catalent Recent Developments
10.7 Sterling Pharma Solutions
10.7.1 Sterling Pharma Solutions Basic Information
10.7.2 Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.7.3 Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.7.4 Sterling Pharma Solutions Business Overview
10.7.5 Sterling Pharma Solutions Recent Developments
10.8 Axplora
10.8.1 Axplora Basic Information
10.8.2 Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.8.3 Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.8.4 Axplora Business Overview
10.8.5 Axplora Recent Developments
10.9 Aji Bio-Pharma
10.9.1 Aji Bio-Pharma Basic Information
10.9.2 Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.9.3 Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.9.4 Aji Bio-Pharma Business Overview
10.9.5 Aji Bio-Pharma Recent Developments
10.10 BSP Pharmaceuticals
10.10.1 BSP Pharmaceuticals Basic Information
10.10.2 BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.10.3 BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.10.4 BSP Pharmaceuticals Business Overview
10.10.5 BSP Pharmaceuticals Recent Developments
10.11 Cerbios-Pharma
10.11.1 Cerbios-Pharma Basic Information
10.11.2 Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.11.3 Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.11.4 Cerbios-Pharma Business Overview
10.11.5 Cerbios-Pharma Recent Developments
10.12 Goodwin Biotechnology
10.12.1 Goodwin Biotechnology Basic Information
10.12.2 Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.12.3 Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.12.4 Goodwin Biotechnology Business Overview
10.12.5 Goodwin Biotechnology Recent Developments
10.13 TOT Biopharm
10.13.1 TOT Biopharm Basic Information
10.13.2 TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.13.3 TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.13.4 TOT Biopharm Business Overview
10.13.5 TOT Biopharm Recent Developments
10.14 Huadong Medicine
10.14.1 Huadong Medicine Basic Information
10.14.2 Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.14.3 Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.14.4 Huadong Medicine Business Overview
10.14.5 Huadong Medicine Recent Developments
10.15 Innovent Biologics
10.15.1 Innovent Biologics Basic Information
10.15.2 Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.15.3 Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.15.4 Innovent Biologics Business Overview
10.15.5 Innovent Biologics Recent Developments
10.16 Shanghai Henlius Biotech
10.16.1 Shanghai Henlius Biotech Basic Information
10.16.2 Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
10.16.3 Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product Market Performance
10.16.4 Shanghai Henlius Biotech Business Overview
10.16.5 Shanghai Henlius Biotech Recent Developments
11 ANTIBODY-DRUG CONJUGATES (ADCS) CMO AND CDMO MARKET FORECAST BY REGION
11.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast
11.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country
11.2.3 Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Region
11.2.4 South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Antibody-drug Conjugates (ADCs) CMO and CDMO by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type (2026-2035)
12.1.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type (2026-2035)
12.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Forecast by Application (2026-2035)
12.2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) Forecast by Application
12.2.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (M USD)
Table 4. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application
Table 5. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Comparison by Region (M USD)
Table 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO as of 2025)
Table 11. Global Market Antibody-drug Conjugates (ADCs) CMO and CDMO Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Type (K Units)
Table 27. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (M USD)
Table 28. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) by Type (2020-2025)
Table 29. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Type (2020-2025)
Table 30. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) by Type (2020-2025)
Table 31. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Type (2020-2025)
Table 32. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Price (USD/Unit) by Type (2020-2025)
Table 33. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) by Application
Table 34. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application
Table 35. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Application (2020-2025) & (K Units)
Table 36. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Application (2020-2025)
Table 37. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025) & (M USD)
Table 38. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application (2020-2025)
Table 39. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Growth Rate by Application (2020-2025)
Table 40. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region (2020-2025) & (K Units)
Table 41. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Region (2020-2025)
Table 42. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (M USD)
Table 43. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025)
Table 44. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country (2020-2025) & (K Units)
Table 45. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country (2020-2025) & (K Units)
Table 47. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (M USD)
Table 50. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country (2020-2025) & (K Units)
Table 51. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (M USD)
Table 54. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units) by Region(2020-2025)
Table 55. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Region (2020-2025)
Table 57. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. Lonza Group Basic Information
Table 63. Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 64. Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. Lonza Group Business Overview
Table 66. Lonza Group SWOT Analysis
Table 67. Lonza Group Recent Developments
Table 68. Merck KGaA Basic Information
Table 69. Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 70. Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 71. Merck KGaA Business Overview
Table 72. Merck KGaA SWOT Analysis
Table 73. Merck KGaA Recent Developments
Table 74. WuXi XDC Basic Information
Table 75. WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 76. WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. WuXi XDC Business Overview
Table 78. WuXi XDC SWOT Analysis
Table 79. WuXi XDC Recent Developments
Table 80. Abbvie Basic Information
Table 81. Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 82. Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Abbvie Business Overview
Table 84. Abbvie Recent Developments
Table 85. Piramal Pharma Solutions Basic Information
Table 86. Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 87. Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Piramal Pharma Solutions Business Overview
Table 89. Piramal Pharma Solutions Recent Developments
Table 90. Catalent Basic Information
Table 91. Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 92. Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Catalent Business Overview
Table 94. Catalent Recent Developments
Table 95. Sterling Pharma Solutions Basic Information
Table 96. Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 97. Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Sterling Pharma Solutions Business Overview
Table 99. Sterling Pharma Solutions Recent Developments
Table 100. Axplora Basic Information
Table 101. Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 102. Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Axplora Business Overview
Table 104. Axplora Recent Developments
Table 105. Aji Bio-Pharma Basic Information
Table 106. Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 107. Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Aji Bio-Pharma Business Overview
Table 109. Aji Bio-Pharma Recent Developments
Table 110. BSP Pharmaceuticals Basic Information
Table 111. BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 112. BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. BSP Pharmaceuticals Business Overview
Table 114. BSP Pharmaceuticals Recent Developments
Table 115. Cerbios-Pharma Basic Information
Table 116. Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 117. Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Cerbios-Pharma Business Overview
Table 119. Cerbios-Pharma Recent Developments
Table 120. Goodwin Biotechnology Basic Information
Table 121. Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 122. Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Goodwin Biotechnology Business Overview
Table 124. Goodwin Biotechnology Recent Developments
Table 125. TOT Biopharm Basic Information
Table 126. TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 127. TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. TOT Biopharm Business Overview
Table 129. TOT Biopharm Recent Developments
Table 130. Huadong Medicine Basic Information
Table 131. Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 132. Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Huadong Medicine Business Overview
Table 134. Huadong Medicine Recent Developments
Table 135. Innovent Biologics Basic Information
Table 136. Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 137. Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Innovent Biologics Business Overview
Table 139. Innovent Biologics Recent Developments
Table 140. Shanghai Henlius Biotech Basic Information
Table 141. Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 142. Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 143. Shanghai Henlius Biotech Business Overview
Table 144. Shanghai Henlius Biotech Recent Developments
Table 145. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Region (2026-2035) & (K Units)
Table 146. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 147. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Country (2026-2035) & (K Units)
Table 148. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 149. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Country (2026-2035) & (K Units)
Table 150. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 151. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Region (2026-2035) & (K Units)
Table 152. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 153. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Country (2026-2035) & (K Units)
Table 154. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 155. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Country (2026-2035) & (Units)
Table 156. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 157. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Type (2026-2035) & (K Units)
Table 158. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Type (2026-2035) & (M USD)
Table 159. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Price Forecast by Type (2026-2035) & (USD/Unit)
Table 160. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) Forecast by Application (2026-2035)
Table 161. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (M USD)
Table 4. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application
Table 5. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Comparison by Region (M USD)
Table 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO as of 2025)
Table 11. Global Market Antibody-drug Conjugates (ADCs) CMO and CDMO Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Type (K Units)
Table 27. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (M USD)
Table 28. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) by Type (2020-2025)
Table 29. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Type (2020-2025)
Table 30. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) by Type (2020-2025)
Table 31. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Type (2020-2025)
Table 32. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Price (USD/Unit) by Type (2020-2025)
Table 33. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) by Application
Table 34. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application
Table 35. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Application (2020-2025) & (K Units)
Table 36. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Application (2020-2025)
Table 37. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025) & (M USD)
Table 38. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application (2020-2025)
Table 39. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Growth Rate by Application (2020-2025)
Table 40. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region (2020-2025) & (K Units)
Table 41. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Region (2020-2025)
Table 42. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (M USD)
Table 43. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025)
Table 44. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country (2020-2025) & (K Units)
Table 45. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country (2020-2025) & (K Units)
Table 47. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (M USD)
Table 50. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Country (2020-2025) & (K Units)
Table 51. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (M USD)
Table 54. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units) by Region(2020-2025)
Table 55. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Region (2020-2025)
Table 57. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. Lonza Group Basic Information
Table 63. Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 64. Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. Lonza Group Business Overview
Table 66. Lonza Group SWOT Analysis
Table 67. Lonza Group Recent Developments
Table 68. Merck KGaA Basic Information
Table 69. Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 70. Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 71. Merck KGaA Business Overview
Table 72. Merck KGaA SWOT Analysis
Table 73. Merck KGaA Recent Developments
Table 74. WuXi XDC Basic Information
Table 75. WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 76. WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. WuXi XDC Business Overview
Table 78. WuXi XDC SWOT Analysis
Table 79. WuXi XDC Recent Developments
Table 80. Abbvie Basic Information
Table 81. Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 82. Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Abbvie Business Overview
Table 84. Abbvie Recent Developments
Table 85. Piramal Pharma Solutions Basic Information
Table 86. Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 87. Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Piramal Pharma Solutions Business Overview
Table 89. Piramal Pharma Solutions Recent Developments
Table 90. Catalent Basic Information
Table 91. Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 92. Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Catalent Business Overview
Table 94. Catalent Recent Developments
Table 95. Sterling Pharma Solutions Basic Information
Table 96. Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 97. Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Sterling Pharma Solutions Business Overview
Table 99. Sterling Pharma Solutions Recent Developments
Table 100. Axplora Basic Information
Table 101. Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 102. Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Axplora Business Overview
Table 104. Axplora Recent Developments
Table 105. Aji Bio-Pharma Basic Information
Table 106. Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 107. Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Aji Bio-Pharma Business Overview
Table 109. Aji Bio-Pharma Recent Developments
Table 110. BSP Pharmaceuticals Basic Information
Table 111. BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 112. BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. BSP Pharmaceuticals Business Overview
Table 114. BSP Pharmaceuticals Recent Developments
Table 115. Cerbios-Pharma Basic Information
Table 116. Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 117. Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Cerbios-Pharma Business Overview
Table 119. Cerbios-Pharma Recent Developments
Table 120. Goodwin Biotechnology Basic Information
Table 121. Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 122. Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Goodwin Biotechnology Business Overview
Table 124. Goodwin Biotechnology Recent Developments
Table 125. TOT Biopharm Basic Information
Table 126. TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 127. TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. TOT Biopharm Business Overview
Table 129. TOT Biopharm Recent Developments
Table 130. Huadong Medicine Basic Information
Table 131. Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 132. Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Huadong Medicine Business Overview
Table 134. Huadong Medicine Recent Developments
Table 135. Innovent Biologics Basic Information
Table 136. Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 137. Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Innovent Biologics Business Overview
Table 139. Innovent Biologics Recent Developments
Table 140. Shanghai Henlius Biotech Basic Information
Table 141. Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product Overview
Table 142. Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 143. Shanghai Henlius Biotech Business Overview
Table 144. Shanghai Henlius Biotech Recent Developments
Table 145. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Region (2026-2035) & (K Units)
Table 146. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 147. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Country (2026-2035) & (K Units)
Table 148. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 149. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Country (2026-2035) & (K Units)
Table 150. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 151. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Region (2026-2035) & (K Units)
Table 152. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 153. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Country (2026-2035) & (K Units)
Table 154. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 155. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Country (2026-2035) & (Units)
Table 156. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 157. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Type (2026-2035) & (K Units)
Table 158. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Type (2026-2035) & (M USD)
Table 159. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Price Forecast by Type (2026-2035) & (USD/Unit)
Table 160. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) Forecast by Application (2026-2035)
Table 161. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Antibody-drug Conjugates (ADCs) CMO and CDMO
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD), 2025-2035
Figure 5. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) (2020-2035)
Figure 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Product Life Cycle
Figure 13. Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Share by Manufacturers in 2025
Figure 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Share by Manufacturers in 2025
Figure 15. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Antibody-drug Conjugates (ADCs) CMO and CDMO Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue in 2025
Figure 18. Industry Chain Map of Antibody-drug Conjugates (ADCs) CMO and CDMO
Figure 19. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market PEST Analysis
Figure 20. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Type
Figure 27. Sales Market Share of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type (2020-2025)
Figure 28. Sales Market Share of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type in 2025
Figure 29. Market Share of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type (2020-2025)
Figure 30. Market Share of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application
Figure 33. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Application (2020-2025)
Figure 34. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Application in 2025
Figure 35. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application (2020-2025)
Figure 36. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application in 2025
Figure 37. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Growth Rate by Application (2020-2025)
Figure 38. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Region (2020-2025)
Figure 39. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025)
Figure 40. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Country in 2024
Figure 43. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country in 2024
Figure 45. U.S. Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Country in 2024
Figure 53. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country in 2024
Figure 55. Germany Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Region in 2024
Figure 67. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region in 2024
Figure 68. China Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (K Units)
Figure 79. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Country in 2024
Figure 80. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (M USD)
Figure 81. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country in 2024
Figure 82. Brazil Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region in 2024
Figure 92. Saudi Arabia Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Production Market Share by Region (2020-2025)
Figure 103. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units) Growth Rate (2020-2025)
Figure 106. China Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share Forecast by Type (2026-2035)
Figure 111. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Application (2026-2035)
Figure 112. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Antibody-drug Conjugates (ADCs) CMO and CDMO
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD), 2025-2035
Figure 5. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) (2020-2035)
Figure 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Product Life Cycle
Figure 13. Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Share by Manufacturers in 2025
Figure 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Share by Manufacturers in 2025
Figure 15. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Antibody-drug Conjugates (ADCs) CMO and CDMO Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue in 2025
Figure 18. Industry Chain Map of Antibody-drug Conjugates (ADCs) CMO and CDMO
Figure 19. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market PEST Analysis
Figure 20. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Type
Figure 27. Sales Market Share of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type (2020-2025)
Figure 28. Sales Market Share of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type in 2025
Figure 29. Market Share of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type (2020-2025)
Figure 30. Market Share of Antibody-drug Conjugates (ADCs) CMO and CDMO by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application
Figure 33. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Application (2020-2025)
Figure 34. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Application in 2025
Figure 35. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application (2020-2025)
Figure 36. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application in 2025
Figure 37. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Growth Rate by Application (2020-2025)
Figure 38. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Region (2020-2025)
Figure 39. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025)
Figure 40. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Country in 2024
Figure 43. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country in 2024
Figure 45. U.S. Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Antibody-drug Conjugates (ADCs) CMO and CDMO Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Country in 2024
Figure 53. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country in 2024
Figure 55. Germany Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Region in 2024
Figure 67. Asia Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region in 2024
Figure 68. China Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (K Units)
Figure 79. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Country in 2024
Figure 80. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (M USD)
Figure 81. South America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country in 2024
Figure 82. Brazil Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region in 2024
Figure 92. Saudi Arabia Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Production Market Share by Region (2020-2025)
Figure 103. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units) Growth Rate (2020-2025)
Figure 106. China Antibody-drug Conjugates (ADCs) CMO and CDMO Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share Forecast by Type (2026-2035)
Figure 111. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Forecast by Application (2026-2035)
Figure 112. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share Forecast by Application (2026-2035)
